Effect of loss of heterozygosity of the c-kit gene on prognosis after hepatectomy for metastatic liver gastrointestinal stromal tumors

Cancer Science

Volumn 98, Issue 11, 2007, Pages 1734-1739

  Kikuchi, Hirotoshi ^a   Yamamoto, Masayoshi ^a   Hiramatsu, Yoshihiro ^a   Baba, Megumi ^a   Ohta, Manabu ^a   Kamiya, Kinji ^a   Tanaka, Tatsuo ^a   Suzuki, Shohachi ^a   Sugimura, Haruhiko ^a   Kitagawa, Masatoshi ^a   Kanai, Toshikazu ^b   Kitayama, Yasuhiko ^c   Kanda, Tatsuo ^d   Nishikura, Ken ^d   Konno, Hiroyuki ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HAMAMATSU MEDICAL CENTER   (Japan)

^c SHIZUOKA SAISEIKAI GENERAL HOSPITAL   (Japan)

^d NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; IMATINIB; KI 67 ANTIGEN; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DNA EXTRACTION; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABELING INDEX; LIVER METASTASIS; LIVER RESECTION; MALE; METASTASIS POTENTIAL; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

EID: 34748910107     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00592.x     Document Type: Article

References (32)

1. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-80.
2. Lux ML, Rubin BP, Biase TL et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000; 156: 791-5.
3. Rubin BP, Singer S, Tsao C et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61: 8118-21.
4. Hirota S, Nishida T, Isozaki K et al. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 2001; 193: 505-10.
5. Hirota S, Ohashi A, Nishida T et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125: 660-7.
6. Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-10.
7. DeMatteo RP, Lewis JJ, Leung D et al. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-8.
8. Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 2002; 38: S37-8.
9. Sturgeon C, Chejfec G, Espat NJ. Gastrointestinal stromal tumors: A spectrum of disease. Surg Oncol 2003; 12: 21-6.
10. Buchdunger E, Cioffi CL, Law N et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-45.
11. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-6.
12. van Osteroom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: A phase I study. Lancet 2001; 358: 1421-3.
13. George DD, Robert B, Charles DB et al. NCCN task force report: Optimal management of patients with gastrointestinal stromal tumor (GIST) - expansion and update of NCCN clinical practice guidelines. J NCCN 2004; 2 (Suppl): S1-28.
14. Tamborini E, Bonadiman L, Greco A et al. A new mutation in the KIT ATP pocket cause acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004; 127: 294-9.
15. Wakai T, Kanda T, Hirota S, Ohashi A, Shirai Y, Hatakeyama K. Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumor is associated with a second KIT mutation. Br J Cancer 2004; 90: 2059-61.
16. Chen LL, Trent JC, Wu EF et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004; 64: 5913-1.
17. Debiec-Rychter M, Cools J, Dumez H et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005; 128: 270-9.
18. Wardelmann E, Thomas N, Merkelbach-Bruse S et al. Acquired resistance to imatinib in gastrointestinal stromal tumors caused by multiple KIT mutations. Lancet Oncol 2005; 6: 249-51.
19. Antonescu CR, Besmer P, Guo T et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11: 4182-90.
20. Dagher R, Cohen M, Williams G et al. Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002; 8: 3034-8.
21. Mudan SS, Conlon KC, Woodruff JM et al. Salvage surgery for patients with recurrent gastrointestinal sarcoma: Prognostic factors to guide patient selection. Cancer 2000; 88: 66-74.
22. DeMatteo RP, Shah A, Fong Y et al. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001; 234: 540-8.
23. Kikuchi H, Yamashita K, Kawabata T et al. Immunohistochemical and genetic features of gastric and metastatic liver gastrointestinal stromal tumors: Sequential analyses. Cancer Sci 2006; 97: 127-32.
24. Igarashi H, Sugimura H, Maruyama K et al. Alteration of immunoreactivity by hydrated autoclaving, microwave treatment, and simple heating of paraffin-embedded tissue sections. APMIS 1994; 102: 295-307.
25. Fujimoto Y, Nakanishi Y, Yoshimura K, Shimoda T. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: Analysis of results in 140 surgically resected patients. Gastric Cancer 2003; 6: 39-48.
26. Wang X, Mori I, Tang W et al. Helpful parameter for malignant potential of gastrointestinal stromal tumors (GIST). Jpn J Clin Oncol 2002; 32: 347-51.
27. Taniguchi M, Nishida T, Hirota S et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59: 4297-300.
28. Antonescu CR, Sommer G, Sarran L et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003; 9: 3329-37.
29. Ernst SI, Hubbs AE, Przygodzki RM, Emory TS, Sobin LH, O'Leary TJ. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Laboratory Invest 1998; 78: 1633-6.
30. El-Rifai W, Sarlomo-Rikala M, Andersson LC, Knuutila S, Miettinen M. DNA sequence copy number changes in gastrointestinal stromal tumors: Tumor progression and prognostic significance. Cancer Res 2000; 60: 3899-903.
31. Yamashita K, Igarashi H, Kitayama Y et al. Chromosomal numerical abnormality profiles of gastrointestinal stromal tumors. Jpn J Clin Oncol 2006; 36: 85-92.
32. Fukasawa T, Chong JM, Sakurai S et al. Allelic loss of 14q and 22q, NF2 mutation, and genetic instability occur independently of c-kit mutation in gastrointestinal stromal tumor. Jpn J Cancer Res 2000; 12: 1241-9.